Purpose Patients who participate in questionnaire surveys, clinical studies and clinical trials can be different from patients who do not participate. The occurrence and direction of this response, participation or ascertainment bias is unpredictable, and can harm the external validity of medical research. Methods We compared the characteristics of patients with intracranial tumours who participated in a psychological study of inspection time with the characteristics of patients who did not participate for a number of reasons. Results Of 178 newly diagnosed adults with intracranial tumours, 136 (76%) were eligible, of whom 76 (56%) participated and 34 (25%) declined. There were no significant differences in terms of age and sex of the patients who participated and those who declined. When the participation group was combined with those who were ineligible and those who declined, the majority of patients in the combined cohort (n=152) had a WHO grade III or IV glioma (high-grade glioma) (48.0%), and only 13.2% had a WHO grade I or II glioma (low-grade glioma). However, only 38.2% of those who participated had a WHO grade III or IV glioma, and 23.7% had a WHO grade I or II glioma. Comparisons of the participation vs. ineligible and declined groups revealed there was a significant difference (p=0.002) between the ratio of high-grade to low-grade gliomas in the total and recruited cohorts. Comparisons of only the participation vs. declined groups approached significance (p=0.051). WHO grade III and IV glioma patients were underrepresented, and WHO grade I or II glioma patients were over-represented in the study group. Conclusions Noninterventional, non-therapeutic applied neuropsychological studies in neuro-oncology are susceptible to bias since the spectrum of neuropathologies in recruited patients can be significantly different from that of the total cohort. These data could help anticipate recruitment rates for applied neuropsychological studies in clinical neuro-oncology and may help anticipate likely selection biases amongst those who participate.
Introduction
Recruiting participants into clinical research studies is often a difficult task and can ultimately result in an unsuccessful clinical trial [24] . The causes of recruitment difficulties include inter alia the need to recruit vulnerable or seriously ill patients, the necessity to adhere to strict ethical guidelines, indirect pathways to patient recruitment and changes in staff involved in trial recruitment. A well-planned recruitment strategy involving collaboration with other health-care professionals and flexibility is essential [14] .
Selective recruitment, in addition to other factors, can compromise the integrity of a clinical study, and low participation rates from patients who are approached increases the likelihood of a sample bias [1, 23] . Thus, in a prospective, observational study of brain arteriovenous malformations, there was a significant difference between those who consented and those who either refused or could not consent in terms of some clinical features, likelihoods of treatment and likelihood of intracranial haemorrhage [1] .
Here we describe our experience in recruiting neurosurgical inpatients into an ethically approved, prospective, externally funded, non-therapeutic, non-interventional, applied neuropsychological study in brain tumour patients. Based on the results of a pilot study [25] , this larger prospective study was designed and powered to evaluate the potential benefits of measuring visual inspection time in neuro-oncological patients. The recruitment timetable had been constructed based on an estimated 90-100 supratentorial brain tumour patients per year, with a 70% recruitment rate over 30 months. Estimates of recruitment numbers and rates were based on several previous prospective neuro-oncological studies in the department, one an interventional therapeutic study with 100% compliance [19] , two non-interventional neuroradiological studies with 100% compliance [2, 12] and another noninterventional neuropathological study with >96% compliance [21] , and a prospective audit that suggested about 25% of patients would have cognitive or other problems that rendered them ineligible for neuropsychological studies [6] . A recruitment log of all patients approached was kept from the onset.
After it became apparent that recruitment was falling behind schedule, a dedicated study was performed to analyse the extent of the failure of planned recruitment and to evaluate whether recruitment difficulties may cause bias in the sample.
Methods
The study was focused on patients with newly diagnosed supratentorial intracranial tumours who were to have either a biopsy or surgical resection, and control patients having elective spinal surgery for neurodegenerative conditions. Participation in the study, which was ethically approved (LREC/2002/5/4), involved the completion of: (1) a battery of neuropsychological tests before surgery, including inspection time (total duration 40-60 min), and (2) a follow-up testing session postoperatively, prior to discharge, in which the patient repeats a number of the tasks (total duration 30 min). A third session for only the brain tumour patients took place when the patient returned for a follow-up outpatient appointment (duration 30 min).
In order to optimise recruitment, the research associate (JLS) consulted the admissions diary and the preadmission staff for relevant wards on a daily basis in order to obtain names of suitable elective cases. Recruitment posters detailing information about the study were placed on the wards. All ward medical and paramedical staff were informed about the study, and were also asked directly by IRW and by the research associate to inform them of any suitable admissions. A recruitment log was kept, tracking all potential brain tumour participants, their demographic characteristics and the reasons for their non-participation.
Data were analysed using 2×2 tables and nonparametric statistics on SPSS software.
Results
A total of 178 newly diagnosed patients were admitted for surgical biopsy or resection of a supratentorial intracranial tumour to the Department of Clinical Neurosciences between April 2006 and December 2007. Of these, 136 (76%) fulfiled study eligibility criteria. Forty-two (24.0%) of the 178 patients were ineligible to take part in the study for medical reasons (severe visual acuity or visual field defects, dysphasia or impaired mental status that precluded obtaining informed consent, or sensorimotor impairments that prevented the patient from being transported to the testing office), or because of co-morbidities such as Down syndrome, schizophrenia or chronic alcoholism. Of the cohort eligible for the study, only 56% participated, since 25% (34 patients) declined and 19% (26 patients) were 'missed' because the research associate was on annual leave (n=13), there was a communication failure between ward medical and nursing staff that left no time for testing (n=7), or the patients were either admitted or transferred to the ward very late on the day before their operation (n=6) (Fig. 1) .
The median age of those brain tumour patients who participated was 52 years (range 17-80), which was not significantly different from those who declined (54 years; range 31-76). Of those brain tumour patients who declined to go in the study, 23 (68%) of the 34 did not give any specific reason for refusal. The remaining 11 patients (32%) stated anxiety about their impending surgery as the reason for declining. There was no significant association between the patient gender and whether or not they agreed to participate in the study (χ² (1)=3.11, p=0.78).
Of the total cohort who either participated, declined or were ineligible (n=152), the majority were subsequently found to have a high-grade glioma (48.0%, WHO III-IV), low-grade glioma (13.2%; WHO I or II), meningi-oma (17.1%) or metastasis (9.9%) (see Table 1 ). However, in the study cohort only 38.2% had a WHO grade III or IV glioma, and 24% had a WHO grade I or II low-grade glioma. This anomaly arose because 66.7% of the patients in the medically 'excluded' ineligible group had WHO grade III or IV gliomas, and only 2.4% of ineligible patients were found to have a WHO grade I or II gliomas.
The 'declined' and 'ineligible' groups were combined to form a single 'non-participation' group and were compared in terms of tumour type with the participating group. This analysis revealed a significant association between the group and tumour type: χ²(4)= 16.79, p= 0.002. This confirms that more WHO grade III or IV glioma patients than expected were not entered into the study and, conversely, a higher number of WHO grade I or II glioma patients than expected did participate.
When the group who declined to take part was compared with the participation group, the association between group and tumour type approached the conventional level of significance [X² (4)=9.46; p=0.051]. Again, this highlights the differences between those who did and did not agree to participate in the study.
Discussion
The patient recruitment phase is often the most problematic aspect of carrying out a research project [9] . In this applied Fig. 1 Flowchart detailing brain tumour patient cohort, eligibility for the study and recruitment neuropsychological project in patients with supratentorial brain tumours, the decline rate was higher in the brain tumour group when compared to a recent interventional brain tumour clinical trial [17] , two non-interventional, non-testing (demanding) clinical studies [2, 12] and an ongoing non-interventional non-'testing' brain tumour clinicopathological study [21] that were also conducted in the unit. Where a reason for declining to participate was given, which only occurred in 32% of cases, the anxiety associated with a new diagnosis of brain tumour combined with the anxiety about having to perform a range of neuropsychological tests was mentioned. Certainly the problems of performing neuropsychological tests in brain tumour patients have been well documented qualitatively but not quantitatively [15] . Potential problems with neuropsychological evaluation in brain tumour patients would seem maximal in WHO grade III and IV glioma patients before the first surgery since most studies have been done successfully on both low-and high-grade glioma patients during follow-up [3, 5, 7, 11] .
However, the non-therapeutic nature of the study may also have increased decline rates, since overall only 56% of all eligible brain tumour patients (43% of the entire cohort) were recruited into the study. This is comparable with data from a community-based clinical research study involving young women of an ethnic minority in which 47% of all eligible participants were successfully recruited [22] . Similarly, a mean enrolment proportion of 32.7% across 112 different recruitment sites into a Cardiac Arrhythmia Suppression Trial (CAST) has also been reported [13] . In the recent ISAT trial only 2,143 (22.42%) cases out of 9,559 patients with intracranial aneurysms were recruited into this randomised interventional study [8] . Generally, however, there are very few data in the literature about what influences participation in various clinical trials.
Analysis of the proportion of patients with each tumour type (WHO grade III and IV glioma, WHO grade I and II glioma, meningioma, metastasis or other tumour) in each of the recruitment groups (participated, declined, excluded) revealed significantly more patients with a WHO grade III or IV glioma diagnosis in the ineligible and declined groups compared with the proportion of WHO III or IV glioma patients who participated. This finding is not altogether unexpected given the tendency for patients with malignant gliomas to have more focal and global brain dysfunction than patients with lower grade gliomas or meningiomas [18] . Additionally, these patients tend to present more frequently on an urgent and emergency basis, and as such are often admitted to the hospital ward for only a short while before surgical intervention. Conversely, most patients with WHO grade I and II glioma were recruited into the study. Since most WHO grade I and II glioma patients are treated surgically on an elective basis, and tend to have no focal neurological deficit or significant cognitive dysfunction, this is not surprising [20] . However, as a result of all these factors, WHO grade III and IV glioma patients are under-represented, and WHO grade I and II glioma patients are over-represented. Indeed, it has been previously noted in a prospective neurosurgical study that those recruited were significantly less likely to be either dead or disabled than those not recruited [1] . Another study evaluating stroke also found that those consenting to the study had significantly lower inpatient mortality than those not recruited [16] . Such a disparity may well bias the final outcome of our study, which was to determine differences between inspection time in patients with an intracranial tumour prior to surgery and two control groups. Given the high likelihood that patients with either WHO III or IV gliomas are likely to perform less well than patients with lower grade gliomas [3, 4] , the tumour cohort recruited will score better than a truly representative cohort. Further bias in this study has also occurred because nine of the patients with glioblastoma recruited had their inspection time scores removed since they did not score in the minimally required range.
Although previous studies of cognition in WHO grade III and IV glioma patients generally report greater impairment than those studies focused on WHO grade I and II glioma patients [3, 4] , these studies may actually underestimate the cognitive effects of brain tumours in WHO grade II and IV patients. This will occur since many patients, both in this and other studies, with more severe symptoms decline or are unable to participate [1, 10] . Our experiences highlight the methodological difficulties and potential consent or participation bias when recruiting patients into a non-interventional, neuropsychological study in neuro-oncology.
